A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and
expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid
leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysp...
Age: 18 years - 66+
Gender: All
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when
administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants
who require red blood cell transfusions.
Age: 18 years - 66+
Gender: All
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1
interventional, open-label, biologic assignment-based umbrella study evaluating the
feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses
of TSC...
Age: 18 years - 66+
Gender: All
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Age: 18 years - 66+
Gender: All
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Main objective of this study is to describe and evaluate safety and efficacy of MBG453
(sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine
or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))
Age: 18 - 99 years
Gender: All
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a
protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with
magrolimab may enable the body's immune system to find and destroy the cancer cells. In thi...
Age: 18 years - 66+
Gender: All
Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Age: 50 - 75 years
Gender: All